Clinical Trial Update: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II open-label trial evaluating Tulmimetostat in combination with darolutamide versus darolutamide, and Tulmimetostat with abiraterone, in metastatic h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Darolutamide (darolutamide)
• Tulmimetostat (Tulmimetostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1, Phase 2 | Status: RECRUITING